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httpcense.Abstract Background: Paclitaxel and platinum-based chemotherapy is considered to be a stan-
dard approach for locally advanced and metastatic non-small cell lung cancer (NSCLC). In recent
years, paclitaxel on a weekly schedule in combination with carboplatin has been widely used
because it is associated with a lower incidence of neuropathy and myelosuppression. Otherwise,
only a few studies are available in elderly patients with NSCLC.
Purpose: The aim of our study was to evaluate the efﬁcacy and safety of weekly paclitaxel com-
bined with carboplatin compared with the classic 3-weekly schedule of paclitaxel and carboplatin as
initial therapy and the feasibility of subsequent maintenance therapy versus observation in elderly
patients with locally advanced (stage IIIB) and metastatic (stage IV) NSCLC.
Patients and methods: Ninty patients P65 years with stage IIIB–IV NSCLC were randomly
assigned to one of the following arms: arm1, paclitaxel 90 mg/m2 weekly for 3 of 4 weeks with car-
boplatin (area under the curve {AUC} = 6) on day 1 of each 4 week cycle; and arm 2, paclitaxel
200 mg/m2 with carboplatin (AUC= 6) on day 1 of each 3-week. After four cycles of chemother-
apy, those with objective response or stable disease were randomized to weekly paclitaxel (70 mg/
m2, 3 of 4 weeks) or observation as maintenance therapy. Primary end point was response while sec-
ond end points included survival and toxicity.00700390.
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486 H.M. El-Shenshawy et al.Results: Eighty-six patients were evaluable for response, overall responses were recorded in
42.9% in arm 1 versus 31.8% in arm 2; stable disease was 38.1% in arm 1 versus 27.3% in arm
2 and progressive disease was 19% in arm 1 versus 40.9% in arm 2. The median time to progression
and median survival times were 7 months and 10.8 months in arm 1 versus 5.6 months and
9 months in arm 2, respectively. The 1-year survival rates were 47.6% in arm 1 versus 36.4% in
arm 2. Grade 3/4 anemia was more common in arm 1 (23.8%) than arm 2 (9.1%). Grade 3/4 neu-
tropenia and febrile neutropenia occurred in 14.3% and 4.7% in arm 1 versus 22.7% and 9.1% in
arm 2. Grade 2/3 neuropathy occurred in 4.7% in arm 1 versus 13.6% in arm 2.
Conclusions: Efﬁcacy was similar between the weekly regimen and the standard regimen of car-
boplatin and paclitaxel for elderly patients with advanced NSCLC and may be advantageous based
on its favorable tolerability proﬁle.
ª 2012 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.Introduction
Lung cancer is the most common cause of cancer-related
deaths in Western countries [1]. Non-small cell lung cancer
(NSCLC) constitutes approximately 80% of all cases of lung
cancer [2]. More than 50% of advanced NSCLC occurs in peo-
ple aged >65 years [3], with median age at diagnosis of
70 years [4].
Treatment of advanced NSCLC is palliative; the aim is to
prolong survival with less deterioration in quality of life [5].
The recommended ﬁrst-line treatment of advanced NSCLC
currently involves platinum-based two-drug combination
chemotherapy [6]. However, the efﬁcacy of platinum-based
doublets in elderly (agedP 70 years) patients with advanced
NSCLC has not been studied extensively [7]. Therefore, the
safety and efﬁcacy data generated from randomized clinical
trials cannot be extrapolated to elderly NSCLC patients.
The choice of chemotherapy regimen for elderly NSCLC pa-
tients is inﬂuenced by both physician and patient-related fac-
tors. Perception of higher toxicity and lower efﬁcacy in
elderly patients by both the treating physician and the pa-
tient may result in suboptimal therapeutic selections. It is
therefore important that elderly patients are adequately rep-
resented in clinical trials, and it is also important to conduct
prospective studies exclusively in elderly patients. Treatment
of elderly patients with systemic chemotherapy may be lim-
ited by various factors such as comorbid illnesses, physio-
logic changes in functional status, organ function and drug
pharmacokinetics [8].
Randomized clinical trials have established the utility of
single-agent chemotherapy in elderly patients [9,10]. The el-
derly Lung Cancer Vinorelbine Study compared treatment
with vinorelbine plus best supportive care to best supportive
care alone [11]. Although the study did not complete its
planned accrual, both survival and quality of life beneﬁts were
noted for the elderly patients treated with chemotherapy. The
Multi-center Italian Lung Cancer Elderly Study compared sin-
gle-agent therapy with vinorelbine or gemcitabine with the
combination of the same drugs [12]. There was no added ben-
eﬁt when the two drugs were given in combination compared
with single-agent therapy alone. However, toxicity was more
pronounced with the combination regimen. Because plati-
num-based doublet regimens are superior to single-agent ther-
apy with either a platinum compound or a novel agent alone
[13–16], there is a need to evaluate platinum-based combina-
tion regimens in elderly patients.The dosing regimen for paclitaxel exists in several different
permutations; the most common ones being every-3-week or
weekly schedules. Studies using weekly single-agent paclitaxel
have shown that this schedule is well tolerated and provides
greater dose intensity when compared with the more conven-
tional schedules. Chang et al. [17] and Akerley et al. [18] have
reported results of trials using the weekly schedule to treat pa-
tients with advanced NSCLC; they achieved response rates of
32% and 39%, respectively. Rossi et al. [19] reported response
rate of 37.5% with weekly paclitaxel in elderly patients with
advanced NSCLC. However, weekly paclitaxel in elderly pa-
tients with advanced NSCLC in Fidias et al. [20] study had
an overall response rate of 23%, median time to failure of
5.2 months, median survival time of 10.3 months and survival
rates after 1 and 2 years of 45% and 22%, respectively, and in
Yasuda et al. [21] study had an overall response rate of 49%
and median survival time of 55 weeks.
The combination of paclitaxel of (225 mg/m2) and carbo-
platin (area under the curve {AUC} = 6) administered every
3 weeks is the most commonly used chemotherapy regimen
in the United States for treatment of advanced and metastatic
NSCLC. The response rate with 3-weeks paclitaxel and carbo-
platin ranges from 17% to 25%, with median survival times
averaging approximately 8 months [22–24]. Although the reg-
imen is well tolerated, it is associated with a 10–17% incidence
of neuropathy [22–24]. Suresh et al. [25] reported overall re-
sponse rate of 19%, median survival duration of 31 weeks
and 1-year survival rate of 33% and grade 3 neuropathy of
9.5% with 3-weeks paclitaxel and carboplatin in elderly pa-
tients with advanced NSCLC. Sakakibara et al. [26] reported
an overall response rate of 53% and median progression-free
survival of 5.6 months and grade 3/4 neuropathy of 25% with
3-week paclitaxel and carboplatin in elderly patients with ad-
vanced NSCLC.
Weekly regimens of paclitaxel in combination with carbo-
platin were developed in an attempt to increase the overall efﬁ-
cacy and decrease the expected toxicities. Another potential
advantage to administration of paclitaxel at frequent, low dose
is its ability to inhibit tumor neoangiogenesis [27]. Suresh et al.
[8] reported that administration of carboplatin every 4 weeks
in combination with weekly paclitaxel for 3 of 4 weeks associ-
ated with the best therapeutic index among other different
weekly schedules. The median survival was 11.3 months, the
1-year survival rate was 47%, the overall response rate was
32% and grade 3/4 neuropathy was 5% with this regimen.
The impressive safety proﬁle of the weekly schedule makes this
Weekly paclitaxel combined with carboplatin versus the standard 487regimen worthy of evaluation for the treatment of elderly
NSCLC patients. Therefore, we performed a randomized
study to determine the efﬁcacy and toxicity of the weekly
schedules of paclitaxel in combination with carboplatin and
compare its results with the standard every 3-weeks regimen
for elderly patients with advanced or metastatic NSCLC.
Patients and methods
Patients selection
Between January 2003 and October 2008, 90 previously un-
treated elderly patients with advanced NSCLC who attended
to department of clinical oncology and nuclear medicine at
Mansoura University Hospital and Department of Clinical
Oncology at Mansoura Health Insurance Clinic, were ran-
domly assigned onto the initial therapy phase of our prospec-
tive study. Previously untreated patients were eligible for the
study if they were at least 65 years of age and had histologi-
cally or cytologically conﬁrmed, inoperable, stage IIIB or IV
NSCLC. Patients had to have at least one bidimensionally
measurable lesion that had not been previously irradiated.
Three patients in arm 1 and one patient in arm 2 refuse to con-
tinue in our randomized study, only 86 patients (42 patients in
arm 1 and 44 patients in arm 2) completed at least two cycles
of study treatment and were assessable for survival, tumor re-
sponse and toxicity.
The Eastern Cooperative Oncology Group (ECOG) perfor-
mance status (PS) had to be 0–2, and patients had to have
a life expectancy of P12 weeks and adequate hematologic
(absolute granulocyte countP 1,500/IL and plateletsP
100,000/IL), renal (creatinine 6 2 mg/dL), and hepatic (AST/
ALT 6 2.5 · upper limit of normal and bilirubin 6 1.5 · upper
limit of normal) function. Prior chemotherapy was not al-
lowed. Patients with measurable neuropathy, active serious
infection, or other serious underlying medical conditions were
ineligible. Written informed consent was obtained from all pa-
tients before enrollment.
Pretreatment evaluations included a complete physical
examination, a complete blood count with differential, platelet
counts, hemoglobin, and the following serum chemistry tests:
electrolytes, blood urea nitrogen, creatinine, alkaline phospha-
tase, SGOT, and total and direct bilirubin. All sites of disease
were documented by computed tomography or magnetic reso-
nance imaging. Brain computed tomography and bone scan
were performed as clinically indicated.
Treatment plan
Patients enrolled onto this study received an initial phase of
therapy that was followed by maintenance therapy for those
patients achieving an objective response or stable disease with
initial therapy. In the initial therapy phase, patients on arm 1
received paclitaxel 90 mg/m2 weekly for 3 of 4 weeks over 3 h
with carboplatin (area under the curve {AUC} = 6) on day
1 of each 4 week cycle; and patients on arm 2 received paclit-
axel 200 mg/m2 over 3 h with carboplatin (AUC= 6) on day
1 every 3 weeks. Premedication administered 30–60 min before
paclitaxel consisted of dexamethasone 20 mg intravenously
(IV), diphenhydramine 50 mg IV, and a histamine 2 blocker
(such as cimetidine 300 mg or ranitidine 50 mg IV).
Patients who experienced complete response, partial re-
sponse, or stable disease after four cycles of therapy in eitherarm of the study were randomized to the maintenance phase
of therapy with weekly paclitaxel or observation. Each
cycle of maintenance chemotherapy consisted of paclitaxel
70 mg/m2 weekly over 3 h for 3 of 4 weeks. Maintenance
therapy continued until disease progression, development of
intercurrent illness, intolerable toxicity, patient refusal of fur-
ther treatment, or investigator decision to terminate treatment.
A maximum of two dose-level reduction was permitted per
patient in the initial phase, but only one reduction was allowed
during the maintenance phase. During the initial phase, the
dose of carboplatin was reduced to achieve AUC of 5 and
4 mg/mL/min, respectively, with each reduction. In arm 1, pac-
litaxel dose was reduced to 85 and 70 mg/m2, respectively, with
each reduction. In arm 2, paclitaxel was reduced to 175 and
150 mg/m2, respectively, with each reduction, For the mainte-
nance phase, paclitaxel dose could be reduced to 50 mg/m2.
Both paclitaxel and carboplatin were reduced by one dose level
if the ANC nadir was no more than 800/lL and/or the platelet
count were 50,000/lL or lower. Paclitaxel was reduced by one
level for grade 2 neuropathy, and patients were removed from
the study for grade 3 or worse, neuropathy. Paclitaxel was
withheld for grade 3 fatigue, arthralgias, or myalgias until res-
olution to no worse than grade 2, and then resumed with a
reduction of dose by one level. Paclitaxel was decreased by
one dose level for bilirubin levels between 1.5 and 2.0 mg/dL,
or withheld for levels higher than 2.0 mg/dL until resolution
to no more than 2.0 mg/dL, then restarted at one dose level
lower. For all other grade 3 or 4 toxicities, treatment was with-
held until resolution to no worse than grade 2; treatment was
then resumed with study medications reduced by one dose
level.
Assessment of efﬁcacy and safety
Complete tumor assessment was undertaken every two cycles
during the initial phase therapy of the study and every
12 weeks during the maintenance phase. Responses were as-
sessed by World Health Organization criteria. Toxicity was
graded and assessed every cycle using the National Cancer
Institute common toxicity criteria, version 2.
Statistical analysis
Pretreatment characteristics of both treatment arms were com-
pared using the Chi square test. The objective response rate
was deﬁned as the percentage of patients achieving a complete
response (CR) or partial response (PR) at the end of the initial
therapy phase. Response rates and incidence of toxicity were
compared using the Chi square test. Toxicities by grade were
tabulated by each treatment arm during the initial and mainte-
nance phases. Time to disease progression was measured from
the date of entry into the trial up to time of treatment failure or
disease progression and was characterized using the Kaplan–
Meier equations. The overall survival rate was measured from
the date of entry into the trial up to time of death or up to the
date of the last follow-up. Overall survival rate was also char-
acterized using Kaplan–Meier method. Survival curves were
calculated from the life tables. Signiﬁcance of differences be-
tween survivals curves were calculated using the Kaplan–Meier
method. The 1-year and 2-year survival and progression-free
survival were calculated using the Chi square test. Mann–
Whitney U test was used to compare the median survival
and median time to progression in both treatment groups.
488 H.M. El-Shenshawy et al.Conﬁdence intervals (CIs) were calculated using Cox’s propor-
tional hazard model. P value is considered signiﬁcant if it is
<0.05.
Informed consent was obtained from all patients, and eth-
ical committee approved was received by our participating
center.
The randomization scheme was a permuted block design
with an equal probability of assignment to either treatment
arms.
The primary efﬁcacy end point was overall response rate
(ORR). The secondary efﬁcacy end points were overall patient
survival and toxicity.
Results
Patient characteristics
Between January 2003 and October 2008, 90 previously un-
treated elderly patients with advanced NSCLC were random-
ized to either paclitaxel 90 mg/m2 weekly for 3 of 4 weeks
with carboplatin (area under the curve {AUC} = 6) on day
1 (arm 1); or paclitaxel 200 mg/m2 with carboplatin
(AUC= 6) on day 1 every 3 weeks (arm 2). Four patients
(three patients in arm 1 and one patient in arm 2) were ex-
cluded from our randomized study because they could not
be subsequently contacted. Only 86 patients (42 patients in
arm 1 and 44 patients in arm 2) completed at least two cycles
of study treatment and were assessable for survival, tumorTable 1 Patients characteristics.
Parameter Weekly paclitaxel
No. %
n= 42
Age
65–70 years 26 61.9
>70 years 16 38.1
Median 68
Range 65–76
Sex
Male 28 66.7
Female 14 33.3
Stage
IIIB 16 38.1
IV 26 61.9
Performance status
PS 0 & 1 36 85.7
PS 2 6 14.3
Pathology
Squamous cell carcinoma 24 57.1
Adenocarcinoma 14 33.3
Large cell carcinoma 4 9.6
Cycles completed
Total 32 76.2
Median 4 (range: 3–4)
Maintenance therapy
Maintenance paclitaxel 20 58.8
Observation 14 41.2response and toxicity. Progression of disease was by far the
most common reason for discontinuation in initial phase (8 pa-
tients in arm 1 and 18 patients in arm 2). After four cycles of
chemotherapy, 60 patients with objective response or stable
disease (34 patients in arm1 and 26 patients in arm 2) were ran-
domized to weekly paclitaxel (70 mg/m2, 3 of 4 weeks) or
observation as maintenance therapy.
Patient baseline characteristics for the initial therapy phase
were comparable across both treatment arms (Table 1). There
was higher percentage of males than females in each treatment
arm, with 66.7% males in arm 1 versus 70.7% males in arm 2.
Median age was 68 years (range, 65–76 years) in arm 1 versus
69 years (range, 65–77 years) in arm 2. The percentage of pa-
tients with an ECOG PS of 0 or 1 to 2 was 85.7% and
14.3% in arm 1 versus 86.4% and 13.6% in arm 2, respec-
tively. Stage IIIB was found in 38.1% in arm 1 versus 40.9%
in arm 2 however, stage IV was found in 61.9% in arm 1 versus
59.1% in arm 2. Thirty-two (76.2%) patients in weekly group
versus 24 (54.5%) patients in the 3-weekly group received the
planned number of treatment cycles.
Efﬁcacy
The objective response rate observed at the end of initial ther-
apy was 42.9% for arm 1 versus 31.8% for arm 2, the differ-
ence was statistically insigniﬁcant (P= 0.074; Hazard Ratio:
0.607; 95% CI: 0.462–5.586). Stable disease was 38.1% in
arm 1 versus 27.3% in arm 2 however; disease progression3-Weeks paclitaxel P value
No. %
n= 44
26 59.1 0.821
18 40.9
69 0.931
65–77
32 70.7 0.792
12 27.3
18 40.9 0.912
26 59.1
38 86.4
6 13.6 0.936
26 59.1
16 36.4 0.789
2 4.5
24 54.5 0.072
4 (range: 2–4) 0.968
16 61.5 0.442
10 38.5
Table 2 Tumor response in both treatment groups
Response Weekly paclitaxel
no.%
3-weeks paclitaxel
no.%
P value
Overall response 18 42.9 14 31.8 0.074
Complete response 2 11.4 0 0
Partial response 16 38.1 14 31.8
Stable disease 16 38.1 12 27.3
Progressive disease 8 19 18 40.9
Control rate* 34 81 26 59.1 0.038
* Including complete response, partial response, and stable disease.
Table 3 Efﬁcacy outcomes in both treatment groups.
Parameter Weekly paclitaxel
(months)
3-weeks
Paclitaxel (months)
P value
Median time to
progression
7 5.6 0.120
Range: (2.5–20) Range: (2–13)
Median overall
survival
10.8 9 0.225
Range: (4–37) Range: (3–29)
Weekly paclitaxel combined with carboplatin versus the standard 489was 19% in arm 1 versus 40.9% in arm 2. The control rate
(including CR, PR, and SD) was 81% in arm 1 versus
59.1% in arm 2, the difference was statistically signiﬁcant
(P= 0.038; Hazard Ratio: 0.838; 95% CI: 0.525–3.338);
(Table 2).
After a median follow-up of 18 months, median survival
time was 10.8 months (range: 4–37 months; 95% CI: 4.819–
16.781) for arm 1 versus 9 months (range: 3–29 months; 95%
CI: 5.338–12.662) for arm 2 (P= 0.225; v2: 1.470); (Table 3).
One- and two-year survival rates were 47.6% and 28.6% for
arm 1 versus 36.4% and 22.7% for arm 2 (P= 0.543; Hazard
Ratio: 0.629; 95% CI: 0.186–2.129, P= 0.671; Hazard Ratio:
0.347; 95% CI: 0.614–2.957); Fig. 1. Median time to diseaseFigure 1 Survival curve for 86 elderly patients treated with paclitaxel
9 months arm II.progression was 7 months (range: 2.5–20 months; 95% CI:
3.686–10.314) for arm 1 versus 5.6 months (range: 2–
13 months; 95% CI: 2.077–9.123) for arm 2 (P= 0.120; v2:
0.960); (Table 3). One year progression-free survival was
23.5% for arm 1 versus 15.3% for arm 2 (P= 0.067; Hazard
Ratio: 0.425; 95% CI: 0.069–2.613); (Fig. 2).
On univariate analyses of the various efﬁcacy parameters
by prognostic factors including disease stage and ECOG PS.
As regard response rate, signiﬁcant differences between the
arms were noted only for patients with stage IIIB disease
and those with ECOG PS 0/1. Patients in arm 1 who had stage
IIIB disease achieved an ORR of 43.8% compared with the
22.2% ORR obtained in arm 2 (P= 0.03). Response rates
of 44.4% and 26.3%, were achieved by patients in arm 1
and arm 2, respectively with ECOG PS 0 to 1 (P= 0.034).
The median time to disease progression was signiﬁcantly high-
er for arm 1 than arm 2 for patients with stage IIIB NSCLC
(8.2 versus 6.1 months, P= 0.041) and ECOG PS 0 to 1 (7.9
versus 5.9 months, P= 0.045). The median survival time for
patients with stage IIIB disease was greater on arm 1 than
on arm 2 (11 versus 9.9 months, P= 0.048). No other sub-
group comparisons were signiﬁcantly different for median time
to progression or median survival time. Although the differ-
ences were not statistically signiﬁcant, it is notable that 1-year
survival rates were greater for arm 1 than for arm 2 across all
subgroups examined. However on multivariate analysis, no
subgroup comparisons were signiﬁcantly different for re-
sponse, median time to progression and median survival time.
Toxicity
There was no evidence of excessive toxicity for elderly patients
treated with the combination regimens. The hematological and
non-hematological toxicities are described in Table 4. Neutro-
penia was the predominant hematological toxicity. Grade 3/4
neutropenia occurred at a higher incidence rate in patients
on arm 2 (22.7%) compared with patients on arm 1 (14.3%);based regimens. The median survival was 10.8 months in arm I and
Figure 2 Time to disease progression among 86 elderdly patients treated with paclitaxel-basde regimens. The median time to disease
progression was 7 months in arm I and 5.6 months in arm II.
Table 4 Patients.
Toxicities Weekly
paclitaxel (%)
3-Weeks
paclitaxel (%)
P value
Grade3/4 Grade3/4
Hematologic toxicities:
Neutropenia 14.3 22.7 0.31
Febrile neutropenia 4.7 9.1 0.89
0.01
Anemia 23.8 9.1 0.036
Thrombocytopenia 19 4.5
Nonhematologic
Toxicities: 4.7 9.1 0.87
Nausea 4.7 9.1 0.92
Vomiting 4.7 13.6 0.062
Peripheral neuropathy* 4.7 22.7 0.021
Fatigue 0 0
Alopecia
* Peripheral neuropathy was grade 2 and 3, no grade 4
490 H.M. El-Shenshawy et al.(P= 0.31). Febrile neutropenia occurred in 4.7% of patients
on arm 1 versus 9.1% of patients on arm 2; (P= 0.89). Grade
3/4 thrombocytopenia occurred in 19% of patients on arm 1
versus 4.5% of patients on arm 2; (P= 0.036). Grade 3/4 ane-
mia was more common in arm 1 (23.8%) than in arm 2 (9.1%);
(P= 0.01). Non-hematologic toxicities were mild in both
treatment arms and there were no major differences in the
non-hematologic toxicity proﬁles between the two treatment
arms. Fatigue and alopecia were the most common non-hema-
tological treatment-related toxicity. Patients on arm 2 experi-
enced more severe fatigue (22.7% versus 4.7% on arm 2 and
1 respectively; P= 0.021) and grade 1/2 alopecia (63.6% ver-
sus 42.8% on arm 2 and 1 respectively; P= 0.021). Grades 2
and 3 neurotoxicity, including neuropathy, peripheral neuritis,
neuritis, and paresthesia were more prevalent in patients on
arm 2 (13.6%), but the incidence was lower for arm 1
(4.7%); (P= 0.06). Nausea and emesis were also less frequent
on the weekly schedule. Toxicity was the reason for treatment
discontinuation in 13.6% of patients given the 3-weekly regi-
men compared with 4.7% of those given the weekly regimen.Of these, the majority of patients withdrew consent because
of toxicity.
After four cycles of chemotherapy, those with objective re-
sponse or stable disease (60 patients) were randomized to
weekly paclitaxel (70 mg/m2, 3 of 4 weeks; 36 patients) or
observation (24 patients) as maintenance therapy. The median
time to disease progression were 8.5 months (range: 3–
20 months) for the paclitaxel group and 3.6 months (range:
2–13 months) for patients on the observation group
(P= 0.001). No grade 4 hematologic and non-hematologic
toxicities reported in the maintenance phase. Progression was
the most common reason for discontinuation of maintenance
therapy and only ten patients discontinued maintenance ther-
apy because of toxicity.
Discussion
Platinum-based chemotherapy has become the cornerstone of
therapy for patients with advanced NSCLC. However, the efﬁ-
cacy of platinum-based chemotherapy has not been evaluated
adequately in elderly patients by prospective trials. To date,
the only prospectively planned evaluation of platinum-based
chemotherapy in elderly patients was conducted in the CAL-
GB 9730 trial [13]. This was a randomized comparison be-
tween paclitaxel administered alone or in combination with
carboplatin for patients with advanced NSCLC. Approxi-
mately 27% of the patients who participated in this study were
older than 70 years. The study design allowed for stratiﬁcation
of patients by age (>70 years versus <70 years). The response
rate and survival rates noted in the elderly patients were com-
parable to those of younger patients in this study. There was a
higher incidence of leucopenia, sepsis, and febrile neutropenia
in elderly patients. The other toxicities were comparable to
that of younger patients. However, because of the smaller
number of elderly patients in the study, these observations
did not reach statistical signiﬁcance. Similar observations have
been made by retrospective analyses of outcome for elderly pa-
tients from randomized trials conducted in advanced NSCLC
[9,28]. Langer et al., conducted a subset analysis of patients
who participated in the ECOG 1594 trial that evaluated four
different chemotherapeutic regimens for the treatment of
Weekly paclitaxel combined with carboplatin versus the standard 491advanced NSCLC [28]. Of the 1207 patients enrolled to the
study, 227 (20%) were older than 70 years and nine patients
(1%) were older than 80 years. Delivery of chemotherapy
was comparable for the younger than 70 and 70 years or older
age groups. Approximately 34% of the younger patients com-
pleted the planned six cycles of chemotherapy, compared with
30% of the elderly cohort. The median survival duration was
8.15 and 8.25 months for the younger and elderly cohorts,
respectively. On the basis of these results, the authors con-
cluded that elderly patients with a good performance status
(ECOG PS 0/1) tolerate and beneﬁt from systemic chemother-
apy similar to younger patients.
To improve the overall tolerability of the taxanes in the el-
derly patients, weekly schedules of both paclitaxel and doce-
taxel have been developed [20,29]. Promising efﬁcacy without
an appreciable increase in toxicity was noted from these stud-
ies. Single-agent paclitaxel given as a 3-h infusion every 3–
4 weeks in patients with advanced NSCLC has produced re-
sponse rates of 11–38% and median survival times of 6.7–
11 months [29]. Because the antiproliferative activity of paclit-
axel is cell cycle speciﬁc, prolonging exposure to the drug
above a threshold concentration should ultimately be more
efﬁcacious than short-term exposure to higher drug concentra-
tions. The relevance of this hypothesis has been supported by
in vitro experiments with a variety of cell lines and suggested
by the results of clinical studies [30,31]. In a phase II study, Fi-
dias et al, treated elderly NSCLC patients with a weekly dose
of paclitaxel (90 mg/m2 for 6 of 8 weeks) [20]. A promising re-
sponse rate (23%) and median survival (10.2 months) were
noted without excessive toxicity. It has been possible to com-
bine weekly paclitaxel with carboplatin [32]. Favorable efﬁcacy
with this combination was noted by a phase II study that was
restricted to the elderly and patients with poor performance
status [33]. In another phase II study, an attenuated dose of
paclitaxel was administered to elderly patients in combination
with carboplatin. This regimen resulted in a response rate of
40% and a median time to progression of 5.5 months [34].
In our randomized study that compares weekly schedule of
paclitaxel combined with carboplatin with standard every 3-
weeks schedule of paclitaxel combined with carboplatin for el-
derly previously untreated patients with advanced NSCLC, the
regimen with better therapeutic index was weekly paclitaxel
(90 mg/m2 administered for 3 of 4 weeks) in combined with
carboplatin (AUC= 6 mg/mL/min every 4 weeks). This study
results in considerable improvement in overall response rate of
42.9% in arm 1 (weekly schedule of paclitaxel combined with
carboplatin) versus 31.8% in arm 2 (standard every 3-weeks
schedule of paclitaxel combined with carboplatin) in elderly
patients with advanced NSCLC. These ﬁndings agree with
many trials that reported an overall response rate ranging from
11% to 43.5% in weekly schedule [8,17–20,25,35,36] and over-
all response rate ranging from 17% to 25% in 3-weeks sche-
dule [22–24]. Our results are slightly higher than some study
as our regimen used as ﬁrst-line treatment in previously un-
treated patients and the median age was slightly lower than
in those studies. However, recent randomized phase II trial
comparing weekly paclitaxel combined with carboplatin with
standard paclitaxel combined with carboplatin in elderly pa-
tients (P70 years) with advanced NSCLC reported high over-
all response rate 55% and 53%, respectively [26].
The median survival time and 1-year and 2-year survival
were longer in weekly schedule than 3-weekly schedule, butthe differences not reach a statistically signiﬁcant difference
in our study. These ﬁndings incorporated with the results of
Suresh et al. [25] and Sakakibara et al. [26]. Although the dif-
ferences in the duration of treatment cycle between the two
arms (4 and 3 weeks, respectively, for arms 1 and 2) could have
contributed to differences in median TTP, the overall survival
and 1-year survival results are comparable between the two
arms. The lower incidence of grade 2/3 neuropathy was
achieved with the weekly paclitaxel regimen despite the same
dose-intensity of paclitaxel on both the arms.
Ukena et al. [37] who compared weekly paclitaxel combined
with carboplatin with standard regimen of 3-weeks paclitaxel
with carboplatin had similar results to our study, they noted
lower incidence of grade 2 or worse sensory neuropathy with
the weekly regimen. Grade 2 or worse. Neutropenia was also
less common with the weekly schedule (35% versus 53%).
Socinski et al. [38] reported that although efﬁcacy was similar
between the two arms, grade 3/4 thrombocytopenia and grade
2-4 anemia were signiﬁcantly more in weekly arm, myalgia/
arthralgia was less common with the weekly arm, and there
was a trend toward a lower incidence of neuropathy and neu-
tropenia. These ﬁndings are in accordance with our results.
Furthermore, patients in the standard arm reported signiﬁ-
cantly more taxane-related adverse effects on the Functional
Assessment of Cancer Therapy (FACT) taxane subscale. Ta-
ken together, the weekly regimen of paclitaxel in combination
with carboplatin can be considered an evidence-based thera-
peutic option for front-line therapy of advanced NSCLC [39].
Neuropathy has always been a concern with the carboplatin
and paclitaxel doublet. In the original phase III trials testing
this regimen [22,23,38,40,41], rates of grade P3 neuropathy
ranged from 11% to 17%. These initial trials usually treated
for six or more cycles. The neuropathy associated with this reg-
imen is typically cumulative. In an analysis of the duration of
therapy trial performed with carboplatin and paclitaxel, 19.9%
of patients experienced grade P2 neuropathy during the ﬁrst
four cycles of therapy, while 43% of patients experienced
grade P2 neuropathy by the time they had received eight cy-
cles of therapy. Both this trial and the trial by Belani et al.
[42] limited the duration of therapy with this regimen to four
cycles and had rates of grade P3 neuropathy of 3–6%, which
was not statistically different when comparing every 3 weeks
versus weekly paclitaxel infusion schedules. These data
strongly support the cumulative aspect of neuropathy with this
regimen and show that severe neuropathy is uncommon with
this regimen when appropriate durations of therapy are used
in this patient population.
Another objective of our study was to evaluate the feasibil-
ity of maintenance therapy with weekly paclitaxel after four
cycles of combination chemotherapy. Four cycles of chemo-
therapy are considered optimal for elderly patients with ad-
vanced-stage NSCLC. Continuation of combination
chemotherapy beyond four to six cycles results in cumulative
toxicity without any improvement in efﬁcacy [43,44]. This
raises the question of whether administration of a single agent
as maintenance therapy might be beneﬁcial because it is asso-
ciated with minimal cumulative toxicity. In randomized phase
II study conducted by Belani et al. [35] with weekly paclitaxel
regimens, patients randomly assigned to maintenance weekly
paclitaxel seemed to have improved efﬁcacy. Therefore, we in-
cluded weekly paclitaxel as maintenance therapy for patients in
both arms of the study after four cycles of combination
492 H.M. El-Shenshawy et al.therapy. Maintenance therapy with paclitaxel delayed the time
to disease progression (8.2 versus 4.8 months) and yielded a
greater median survival time (13.9 versus 8.1 months). These
ﬁndings are in accordance with our results, as the maintenance
therapy with paclitaxel delayed the time to disease progression
(8.5 versus 3.6 months) and yielded also a greater median sur-
vival time (19.5 versus 9.5 months). Despite these interesting
results, no deﬁnitive statement can be made regarding the role
of weekly maintenance treatment with paclitaxel. If the study
sample was larger, there is a possibility that a signiﬁcant effect
may have been identiﬁed. Therapy beyond four cycles with the
same regimen may not be beneﬁcial in elderly patients with ad-
vanced NSCLC [43–45], but the role of nontoxic, low doses of
a single agent in this setting still remains an open question.
Conclusion
Our trial conﬁrms the efﬁcacy and safety of weekly paclitaxel
combined with carboplatin schedule that might be considered
a reasonable choice in elderly patients with advanced NSCLC.
References
[1] A. Jemal, R. Siegel, E. Ward, et al., Cancer statistics, CA
Cancer J. Clin. 58 (2008) 71–96.
[2] A.B. Glassberg, P. Cornett, Lung: non-small cell, in: M.
Dollinger, E.H. Rosenbaum, G. Cable (Eds.), Everyone’s
Guide to Cancer Therapy, Somerville House Books Limited,
Kansas City, MO, 1994, pp. 469–475.
[3] C. Gridelli, F. Perrone, S. Monfardini, Lung cancer in the
elderly, Eur. J. Cancer 33 (1997) 2313–2314.
[4] R.J. Havlik, R. Yancik, S. Longo, et al., The National Cancer
Institute on aging and the National Cancer Institute SEER
collaborative study on comorbidity and early diagnosis in the
elderly, Cancer 74 (Suppl. 7) (1994) 2101–2106.
[5] L.F. Hutchins, J.M. Unger, J.J. Crowley, et al., Under
representation of patients 65 years of age or older in cancer-
treatment trials, N. Engl. J. Med. 341 (1999) 2061–2067.
[6] M.A. Socinski, D.E. Morris, G.A. Masters, et al.,
Chemotherapeutic management of stage IV non-small cell lung
cancer, Chest 123 (Suppl. 1) (2003) 226S–243S.
[7] P.A. Bunn Jr., R. Lilenbaum, Chemotherapy for elderly patients
with advanced non-small cell lung cancer, J. Natl. Cancer Inst.
95 (2003) 341–343.
[8] R. Suresh, B. John, P. Michael, et al., Treatment of elderly non-
small cell lung cancer patients with three different schedules of
weekly paclitaxel in combination with carboplatin: subanalysis
of a randomized trial, J. Thorac. Oncol. 1 (3) (2006) 240–244.
[9] C.I. Langer, J. Manola, P. Bernardo, et al., Cisplatin-based
therapy for elderly patients with advanced non-small cell lung
cancer: implications of Eastern Cooperative Oncology Group
5502, a randomized trial, J. Natl. Cancer Inst. 94 (2002) 173–181.
[10] G. Frasci, v. Lorusso, N. panza, et al., Gemcitabine plus
vinorelbine versus vinorelbine alone in elderly patients with
advanced non-small cell lung cancer, J. Clin. Oncol. 18 (2000)
2529–2536.
[11] The elderly lung cancer vinorelbine Italian study group, Effects
of vinorelbine on quality of life and survival of elderly patients
with advanced non-small cell lung cancer, J. Natl. Cancer Inst.
91 (1999) 66–72.
[12] C. Gridelli, F. Perrone, C. Gallo, et al., Chemotherapy for
elderly patients with advanced non-small cell lung cancer: the
Multicenter Italian Lung Cancer in the Elderly Study (MILES)
phase III randomized trial, J. Natl. Cancer Inst. 95 (2003) 362–
372.[13] R.C. Lilenbaum, I.I.J.E. Herndon, M. List, et al., Single agent
versus combination chemotherapy in patients with advanced
non-small cell lung cancer: a CALGB randomized trial of
efﬁcacy, quality of life and cost-effectiveness, Proc. Am. Soc.
Clin. Oncol. 21 (2002) 1a.
[14] C. Sederholm, Gemcitabine compared with gemcitabine plus
carboplatin in advanced non-small cell lung cancer: a phase III
study by the Swedish Lung Cancer Study Group, Proc. Am. Soc.
Clin. Oncol. 21 (2002) 291a.
[15] A.J. Wozniak, J.J. Crowley, S.P. Balcerzak, et al., Randomized
trial comparing cisplatin with cisplatin plus vinorelbine in the
treatment of advanced non-small cell lung cancer: a Southwest
Oncology Group Study, J. Clin. Oncol. 16 (1998) 2459–2465.
[16] A.B. Sandler, J. Nemunaitis, C. Denham, et al., Phase III trial
of gemcitabine plus cisplatin versus cisplatin alone in patients
with locally advanced or metastatic non-small cell lung cancer, J.
Clin. Oncol. 18 (2000) 122–130.
[17] A. Chang, L. Boros, R. Asbury, et al., Weekly moderate-dose
paclitaxel in stage IV non-small cell lung cancer (NSCLC), Proc.
Am. Soc. Clin. Oncol. 17 (1998) 470a (abstr 1806).
[18] W. Akerley, J. Herndon, M.J. Egorin, et al., Phase II trial of
weekly paclitaxel for advanced non-small cell lung cancer
(NSCLC), Proc. Am. Soc. Clin. Oncol. 18 (1999) 462a (abstr
1783).
[19] D. Rossi, D. Dennetta, M. Ugolini, et al., Weekly paclitaxel in
elderly patients (agedP 70 years) with advanced non-small cell
lung cancer: an alternative choice? Results of a phase II study,
Clin. Lung Cancer 9 (5) (2008) 280–284.
[20] P. Fidias, J.G. Supko, R. Matins, et al., A phase II study of
weekly paclitaxel in elderly patients with advanced non-small
cell lung cancer, Clin. Cancer Res. 7 (12) (2001) 3942–3949.
[21] K. Yasuda, T. Igishi, Y. Kawasaki, et al., Phase II trial of
weekly paclitaxel in previously untreated advanced non-small
cell lung cancer, Oncology 65 (2003) 224–228.
[22] J.H. Schiller, D. Harrington, C.P. Belani, et al., Comparison of
four chemotherapy regimens for advanced non-small cell lung
cancer, N. Engl. J. Med. 246 (2002) 92–98.
[23] K. Kelly, J. Crpwley, P.A. Burn, et al., Randomized phase III
trial of paclitaxel plus carboplatin versus vinorelbine plus
cisplatin in the treatment of patients with advanced non-small
cell lung cancer: a Southwest Oncology Group trial, J. Clin.
Oncol. 19 (2001) 3210–3218.
[24] C.P. Belani, R.B. Natale, J.S. Lee, Randomized phase II trial
comparing cisplatin/etopside versus carboplatin/paclitaxel in
advanced and metastatic non-small cell lung cancer (NSCLC),
Proc. Am. Soc. Clin. Oncol. 17 (3) (1998) 455a (abstr 1751).
[25] R. Suresh, P. Michael, L.V. Renato, et al., Comparison of
outcomes for elderly patients treated with weekly paclitaxel in
combination with carboplatin versus the standard 3-weekly
paclitaxel and carboplatin for advanced non-small cell lung
cancer, Cancer 113 (3) (2008) 542–546.
[26] T. Sakakibara, A. Inoue, S. Sugawara, et al., Randomized
phase II trial of weekly paclitaxel combined with carboplatin
versus standard paclitaxel combined with carboplatin for elderly
patients with advanced non-small cell lung cancer, Ann. Oncol.
8 (2009).
[27] G. Bocci, K.C. Nicolaou, R.S. Kerbel, Protracted low-dose
effects on human endothelial cell proliferation and survival
in vitro reveal a selective antiangiogenic window for vatious
chemotherapeutic drugs, Cancer Res. 62 (2002) 6938–6943.
[28] C.I. Langer, M. Vangel, J. Schiller, et al., Age-speciﬁc
subanalysis of BCOG 1594: ﬁt elderly patients (70–80 years)
with NSCLC do as well as younger pts (<70 years), Proc. Am.
Soc. Clin. Oncol. 22 (2003) 639.
[29] J.D. Hainsworth, H.A. Burris III, S. Litchy, et al., Weekly
docetaxel in the treatment of elderly patients with advanced non-
small cell lung carcinoma: a Minnie Pearl Cancer Research
Network phase II trial, Cancer 89 (2000) 328–333.
Weekly paclitaxel combined with carboplatin versus the standard 493[30] M.S. Geogiadis, E.K. Russell, A.F. Gazdar, et al., Paclitaxel
cytotoxicity against human lung cancer cell lines increases with
prolonged exposure durations, Clin. Cancer Res. 3 (1997) 449–
454.
[31] Z. Zhan, S. Scala, A. Monks, et al., Resistance to paclitaxel
mediated by p-glycoprotein can be modulated by changes in the
schedules of administration, Cancer Chemother. Pharmacol. 40
(1997) 245–250.
[32] R.K. Ramanathan, M.J. Cappazoli, D.L. Trump, et al.,
Escalating doses of weekly paclitaxel in combination with
carboplatin: a phase I study in advanced malignancies, Proc.
Am. Soc. Clin. Oncol. 16 (1999) 166.
[33] T.A. Marsland, D.H. Garﬁeld, M.M. Khan, et al., Sequential
versus concurrent paclitaxel and carboplatin for the treatment of
advanced non small cell lung cancer in elderly patients and
patients with poor performance status: results of two phase II,
multicenter trials, Lung cancer 47 (2006) 111–120.
[34] I.S. Choi, B.S. Kim, S.R. Park, et al., Efﬁcacy of modiﬁed
regimen with attenuated doses of paclitaxel plus carboplatin
combined chemothetrapy in elderly and/or weak patients with
advanced non small cell lung cancer, Lung cancer 39 (2003) 99–
101.
[35] A.P. Belani, J. Barstis, M.C. Perry, et al., Multicenter,
randomized trial for stage IIIB or IV non-small cell lung
cancer using weekly paclitaxel and carboplatin followed by
maintenance weekly paclitaxel or observation, J. Clin. Oncol. 21
(15) (2003) 2933–2939.
[36] J.L. Puiol, B. Mileron, Q. Mclinier, et al., Weekly paclitaxel
combined with monthly carboplatin in elderly patients with
advanced non-small cell lung cancer: a multicenter phase II
study, J. Thorac. Oncol. 1 (4) (2006) 328–334.
[37] D. Ukena, M. Schroeder, I. Dittrich, et al., Phase III
randomized trial comparing paclitaxel carboplatin (PC) every
3 weeks with weekly paclitaxel/carboplatin in patients (pts) with
advanced non small cell lung cancer (NSCLC), Proc. Am. Soc.
Clin. Oncol. 22 (2003) 623 (abstr 2506).
[38] M.A. Socinski, A. Ivanova, K. Bakri, et al., A randomized
phase II trial comparing every 3-weeks carboplatin/paclitaxel
with every 3-weeks carboplatin and weekly paclitaxel inadvanced non-small cell lung cancer, Ann. Oncol. 17 (2006)
104–109.
[39] C.P. Belani, S. Ramalingam, M.C. Perry, et al., Randomized,
phase III study of weekly paclitaxel in combination with
carboplatin versus standard every 3-weeks administration of
carboplatin and paclitaxel for patients with previously untreated
advanced non-small cell lung cancer, J. Clin. Oncol. 26 (3) (2008)
468–473.
[40] G. Scaglioti, F. De Marinis, M. Rinaldi, et al., Phase III
randomized trial comparing three platinum-based doublets in
advanced non-small cell lung cancer, J. Clin. Oncol. 20 (2002)
4285–4291.
[41] M.A. Socinski, M.J. Schell, A. Peterman, et al., Phase III trial
comparing a deﬁned duration of therapy versus continuous
therapy followed by second-line therapy in advanced stage IIIB/
IV non small cell lung cancer, J. Clin. Oncol. 20 (2002) 1335–
1343.
[42] C.P. Belani, R. Larocca, D. Rinaldi, et al., A multicenter phase
III randomized trial for stage IIIB/IV NSCLC of weekly
paclitaxel and carboplatin versus standard paclitaxel and
carboplatin given every three weeks, followed by weekly
paclitaxel, Proc. Am. Soc. Clin. Oncol. 23 (2004) 619.
[43] M.A. Socinski, M.J. Schell, K. Bakri, et al., Second-line, low-
dose weekly paclitaxel in patients with stage IIIB/IV non small
cell lung carcinoma who fail ﬁrst-line chemotherapy with
carboplatin plus paclitaxel, Cancer 95 (2002) 1265–1273.
[44] I.E. Smith, M.E.R. O’Brien, D.C. Talbot, et al., Duration of
chemotherapy in advanced non-small cell lung cancer: a
randomized trial of three versus six courses of mitomtcin,
vinblastine, and cisplatin, J. Clin. Oncol. 19 (2001) 1336–1343.
[45] A. Depierre, E. Quoix, M. Mercier, et al., Maintenance
chemotherapy in advanced non-small cell lung cancer
(NSCLC): a randomized study of vinorelbine (V) versus
observation (OB) in patients (pts) responding to induction
therapy (French Coopperative Oncology Group), Proc. Am.
Soc. Clin. Oncol. 20 (2001) 309a (abstr 1231).
